708
Participants
Start Date
November 30, 2014
Primary Completion Date
October 31, 2015
Study Completion Date
January 31, 2016
Dupilumab
Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms.
Placebo (for Dupilumab)
Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms.
Anniston
Birmingham
Phoenix
Bakersfield
Costa Mesa
Fremont
Long Beach
Los Angeles
Orange
Roseville
Temecula
Trumbull
Miami
Oviedo
Tampa
West Palm Beach
Alpharetta
Atlanta
Columbus
Buffalo Grove
Plainfield
West Des Moines
Overland Park
Rockville
Washington Park
Boston
Farmington Hills
Minneapolis
Plymouth
Saint Joseph
St Louis
Billings
Bozeman
Las Vegas
Verona
Forest Hills
New York
Smithtown
Chapel Hill
Raleigh
Wilmington
Winston-Salem
Tulsa
Portland
Jenkintown
Greer
Arlington
Austin
Bellaire
Houston
San Antonio
Richmond
Seattle
Calgary
Edmonton
Surrey
St. John's
Ajax
Mississauga
Oakville
Ottawa
Peterborough
Richmond Hill
Montreal
Lille
Marseille
Nantes
Berlin
Bochum
Darmstadt
Friedrichshafen
Hamburg
Kiel
Hong Kong
Lucca
Pisa
Roma
Kaunas
Klaipėda
Vilnius
Elblag
Gdansk
Katowice
Poznan
Torun
Warsaw
Busan
Gyeonggi-do
Incheon
Seoul
Stockholm
London
Plymouth
Collaborators (1)
Sanofi
INDUSTRY
Regeneron Pharmaceuticals
INDUSTRY